Monte Rosa Therapeutics, Inc. GLUE 深 滬
已收盤 01-09 16:00:00 美东时间
24.28
-1.030
-4.07%
華盛通- 最 高25.18
- 今 開25.14
- 成交量 567.95万股
- 最 低 23.85
- 昨 收 25.31
- 總市值 15.81亿
- 52周最高 25.77
- 市盈率 靜 --
- 換手率 8.72%
- 52周最低 3.5001
- 委 比 -76.11%
- 總股本 6511.78万
- 歷史最高 45.56
- 量 比 0.95
- 振 幅 5.25%
- 歷史最低 2.44
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%
ANPA周涨近300%，公司获私募大额股份认购；脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%，治疗银屑病新药临床成功>>
01-10 06:27
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
Market-Moving News for January 7th
GLUE: 42% | Monte Rosa Therapeutics shares are trading higher after the company announced it will present interim clinical results from the ongoing Phase 1 study of NEK7-directed MGD MRT-8102. VTYX: 74% |
01-07 20:17
Monte Rosa Therapeutics To Present Interim Clinical Results From The Ongoing Phase 1 Study Of The NEK7-Directed MGD MRT-8102 On Wednesday, January 7, at 8:00 a.m. ET
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and
01-07 05:11
制药巨头竞逐下一个重磅药物
（来源：中国医药报） 转自：中国医药报 今年9月，跨国药企诺华宣布与美国生物技术公司Monte Rosa Therapeutics达成战略合作，共同开发针对免...
2025-12-18 08:39
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
2025-12-17 03:37
Monte Rosa Therapeutics To Present Interim Clinical Results From Ongoing Phase 1/2 Study Of GSPT1-Directed MGD MRT-2359 In mCRPC Patients In Live Conference Call On December 16
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and
2025-12-16 05:03
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company, announced that its management will host a live conference call and webcast on December 16, 2025, at 8:00 a.m. ET. The presentation will feature interim clinical results from the Phase 1/2 study of MRT-2359, a GSPT1-directed molecular glue degrader (MGD), in patients with metastatic castration-resistant prostate cancer (mCRPC). The webcast will be accessible via Monte Rosa’s...
2025-12-15 21:01
